Italfarmaco Secures Managed Entry Agreement for Duvyzat in Georgia
MILAN, Italy, July 31, 2026 talfarmaco S.p.A. announced a managed entry agreement with the Georgian Ministry of Health to...
Duchenne muscular dystrophy
Advertisement
Mesoblast Strengthens Cell Therapy Portfolio with RYONCIL Growth and FDA Progress
NEW YORK, USA / MELBOURNE, Australia, July 29–30, 2026 Mesoblast Limited reported strong commercial and clinical progress for the...
Dyne Therapeutics Advances DMD Program with FDA Acceptance
WALTHAM, Mass., July 20, 2026 Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that the U.S. Food and Drug Administration (FDA)...
Santhera Expands AGAMREE Distribution Across Central Asia and Caucasus
PRATTELN, Switzerland, July 13, 2026 Santhera Pharmaceuticals announced the expansion of its exclusive distribution agreement with Biomedica, extending commercial...
Satellos Reports Positive Six-Month SAT-3247 Data
TORONTO, July 8, 2026 Satellos Bioscience Inc. announced encouraging six-month interim data from its ongoing Phase 2 TRAILHEAD clinical...
Advertisements
Grünenthal Receives Dual FDA Designations for Tegacorat in DMD
AACHEN, Germany, July 8, 2026 Grünenthal has announced that the U.S. Food and Drug Administration (FDA) has granted both...
Santhera Reports Positive Phase 1 AGAMREE Data
Pratteln, Switzerland, July 1, 2026 Santhera Pharmaceuticals announced positive topline findings from a Phase 1 clinical study of AGAMREE®...
Nippon Shinyaku, Elixirgen Sign EXG-7001 DMD Option Deal
KYOTO, Japan, June 26, 2026 Nippon Shinyaku Co., Ltd. announced it has entered into an option agreement with Elixirgen...
Capricor Reaches Key FDA Milestone in DMD
SAN DIEGO, June 26, 2026 Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has scheduled a...
CureDuchenne and Tevard Biosciences Advance DMD Therapy
NEWPORT BEACH, Calif., May 20, 2026 CureDuchenne announced a new partnership expansion with Tevard Biosciences to accelerate development of...
Advertisement
